These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535 [TBL] [Abstract][Full Text] [Related]
8. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic. Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
11. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Shea YF; Ha J; Chu LW Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477 [TBL] [Abstract][Full Text] [Related]
12. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453 [TBL] [Abstract][Full Text] [Related]
13. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902 [TBL] [Abstract][Full Text] [Related]
14. Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease. Lista S; Emanuele E Biomark Med; 2011 Aug; 5(4):411-3. PubMed ID: 21861661 [No Abstract] [Full Text] [Related]
15. Biomarkers of Alzheimer's disease: the present and the future. Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316 [TBL] [Abstract][Full Text] [Related]
16. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
17. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India. Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261 [TBL] [Abstract][Full Text] [Related]
18. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786 [TBL] [Abstract][Full Text] [Related]
19. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease. Parnetti L; Chiasserini D Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669 [TBL] [Abstract][Full Text] [Related]